Compile Data Set for Download or QSAR
Report error Found 40 Enz. Inhib. hit(s) with all data for entry = 12601
TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571673(CHEMBL4871518 | US20250019371, Compound 29)
Affinity DataIC50: 5.00E+3nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571672(CHEMBL4865480 | US20250019371, Compound 28)
Affinity DataIC50: 5.00E+3nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571674(CHEMBL4867597 | US20250019371, Compound 30)
Affinity DataIC50: 5.00E+3nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712841(US20250019371, Compound 26)
Affinity DataIC50: 5.00E+3nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712840(US20250019371, Compound 25)
Affinity DataIC50: 1.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712839(US20250019371, Compound 24)
Affinity DataIC50: 1.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571667(CHEMBL4859967 | US20250019371, Compound 23)
Affinity DataIC50: 1.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571666(CHEMBL4876302 | US20250019371, Compound 22)
Affinity DataIC50: 1.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571671(CHEMBL4873369 | US20250019371, Compound 27)
Affinity DataIC50: 1.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571665(CHEMBL4853758 | US20250019371, Compound 21)
Affinity DataIC50: 1.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712851(US20250019371, Compound 35)
Affinity DataIC50: 1.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712848(US20250019371, Compound 32)
Affinity DataIC50: 3.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571664(CHEMBL4866328 | US20250019371, Compound 20)
Affinity DataIC50: 3.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712849(US20250019371, Compound 33)
Affinity DataIC50: 3.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571663(CHEMBL4855866 | US20250019371, Compound 19)
Affinity DataIC50: 3.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712850(US20250019371, Compound 34)
Affinity DataIC50: 3.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571662(CHEMBL4875573 | US20250019371, Compound 18)
Affinity DataIC50: 3.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571660(CHEMBL4863752 | US20250019371, Compound 16)
Affinity DataIC50: 1.00E+5nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571661(CHEMBL4861802 | US20250019371, Compound 17)
Affinity DataIC50: 1.00E+5nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712847(US20250019371, Compound 31)
Affinity DataIC50: 2.00E+5nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571674(CHEMBL4867597 | US20250019371, Compound 30)
Affinity DataKi: <5.00E+3nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571667(CHEMBL4859967 | US20250019371, Compound 23)
Affinity DataKi: <5.00E+3nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571666(CHEMBL4876302 | US20250019371, Compound 22)
Affinity DataKi: <5.00E+3nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712841(US20250019371, Compound 26)
Affinity DataKi: <5.00E+3nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571671(CHEMBL4873369 | US20250019371, Compound 27)
Affinity DataKi: <5.00E+3nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571672(CHEMBL4865480 | US20250019371, Compound 28)
Affinity DataKi: <5.00E+3nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571673(CHEMBL4871518 | US20250019371, Compound 29)
Affinity DataKi: <5.00E+3nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712851(US20250019371, Compound 35)
Affinity DataKi: <1.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712840(US20250019371, Compound 25)
Affinity DataKi: <1.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712839(US20250019371, Compound 24)
Affinity DataKi: <1.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571665(CHEMBL4853758 | US20250019371, Compound 21)
Affinity DataKi: <1.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571664(CHEMBL4866328 | US20250019371, Compound 20)
Affinity DataKi: <3.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712848(US20250019371, Compound 32)
Affinity DataKi: <3.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571663(CHEMBL4855866 | US20250019371, Compound 19)
Affinity DataKi: <3.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712849(US20250019371, Compound 33)
Affinity DataKi: <3.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571662(CHEMBL4875573 | US20250019371, Compound 18)
Affinity DataKi: <3.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712850(US20250019371, Compound 34)
Affinity DataKi: <3.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571661(CHEMBL4861802 | US20250019371, Compound 17)
Affinity DataKi: >9.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571660(CHEMBL4863752 | US20250019371, Compound 16)
Affinity DataKi: >9.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712847(US20250019371, Compound 31)
Affinity DataKi:  1.68E+5nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent